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Tumour karyotype discriminates between good and bad prognostic
outcome in neuroblastoma
H. Christiansen & F. Lampert
Kinderpoliklinik, Justus-Liebig-University, D-6300 Giessen, West Germany.
Summary In 28 patients with neuroblastoma of different stages the karyotype was determined in the primary
tumour and/or in the metastases by direct chromosome preparation or short term cell culture. In addition,
DNA analysis for the proto-oncogene N-myc was performed for comparison in 10 cases.
Abnormalities (deletions, translocations, derivations) of the short arm of chromosome 1 with the most
frequent breakpoint at lp32 (besides rarer aberrations in other chromosomes) were found in the tumour
karyotype of 15 of 18 (83%) patients with metastatic disease (stage IV) and in 2 of 3 patients with stage III,
but in none of the 7 patients with stages I, II, IV-S who are all alive with no evidence of disease. These 7
surviving patients with good prognosis had a hyperploid tumour karyotype, mainly in the triploid range.
Eleven of the 18 (61%) patients with stage IV and 1 of 3 patients with stage III also contained double
minutes (DMs) and/or homogeneously staining regions (HSRs) in their tumour karyotypes. N-myc
amplification (30 to 60 copies) in the tumour DNA was detected in 2 of 6 (33%) examined cases with stage
IV, in 1 out of 2 examined cases with stage III, and correlated with the presence ofDMs/HSRs.
Life table analysis showed a 90% probability of surviving in patients lacking the lp abnormality as
compared to less than 10% in patients with an aberrant lp chromosome in the tumour cells. We conclude
that tumour karyotype, in particular the structure of the short arm of chromosome 1, is the most important
factor in determining the different outcome in children with neuroblastoma.
After brain tumours neuroblastoma represents the most
common solid tumour in childhood with an annual incidence
of 8 cases per million children under 15 years; most of them
- in contrast to the more frequent childhood leukaemias -
occurring within the first 3 years of life.
The biological behaviour of neuroblastoma is unique and
still puzzling to paediatric oncologists in that there is
spontaneous regression in congenital tumours (even in the
metastatic stage) and an almost 100% survival rate in
localized tumours as compared to a less than 10% survival
chance in non-localized, disseminated tumours in children
over 1 year of age in spite of intensive chemotherapy
(Berthold et al., 1986). Besides known prognostic factors
such as age and tumour stage additional clinical factors
useful in predicting outcome, such as serum ferritin and
histologic type, have recently been emphasized (Evans et al.,
1987). Also, the DNA properties of neuroblastoma cells such
as the increased copy number of the proto-oncogene N-myc
(Brodeur et al., 1984; Seeger et al., 1985) or the increased
expression of the oncogene (Rosen et al., 1986) were found
to be associated with progressive growth of the tumour.
That tumour karyotype may be important in the prognosis
of human neuroblastoma was proposed by us after we
obtained tumour cytogenetic data in a series of 14 children
with neuroblastoma (Franke et al., 1986a). In an extended
series of 28 patients with all the different tumour stages we
now confirm the presence or absence of the chromosome 1
short arm abnormality as the most decisive factor charac-
terizing the different biological behaviour of neuroblastoma
cell clones and thus the clinical outcome.
Materials and methods
Patients were registered and prospectively treated within the
consecutive Neuroblastoma Trials NB 79, NB 82, and NB 85
of the German Paediatric Oncology Group which allowed
uniform treatment, documentation, pathological evaluation,
and continuous control of all clinical parameters (Berthold et
al., 1986).
Tumour tissue samples were collected at operation or sent
in by express mail, and were taken either prior to or at least
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2 months after chemotherapy. Samples were immediately
transferred to short-term cultures for 3 h, and/or 2, 3 and at
most up to 8 days. Methods pertaining to chromosome
preparation from solid tumours have been described
previously (Franke et al., 1986b). Chromosome preparations
of bone marrow metastases were performed after cell
synchronisation with methotrexate. Chromosomes were G-
banded with 3% Giemsa solution (pH 6.8) after pre-
treatment with trypsin. The best banded metaphases were
photographed and karyotyped. In the majority of the
patients more than 20 tumour metaphases could be analyzed.
DNA analysis of the N-myc gene from the same tumour
cell material that was used for chromosome study could be
performed in 10 patients. Isolated DNA was digested with
EcoRI, electrophoresed, and transferred on to filter
membranes (Du Pont). N-myc amplification was tested with
the blotting method (Southern) using the probe NB-1
(Schwab et al., 1983) which detects 2.0Kb EcoRI fragments.
The extent of N-myc amplification was confirmed by dot-
blot analyses via serial dilution of the tumour-DNA.
Results
Chromosomes could be successfully prepared and analyzed
from neuroblastoma tissue in 28 patients out of a total of
about 90 patients examined.
The clinical and the most important cytogenetic data such
as the lp abnormality, DMs and HSRs, including N-myc
copies in the tumour where DNA analysis was performed,
are summarized in Table I. In Table II the complete tumour
karyotypes, including the number of cells counted and
analyzed are listed. In the bone marrow preparations diploid
cells of normal haematopoiesis were also found and could be
excluded. The tumour cell preparations showed cell popu-
lations of clonal origin. In only a few cases 1 to 3 sub-
populations with minor cytogenetic variations were seen
(Table II).
Of the 12 infants studied, 4 of the 6 with stage IV disease
are dead; the others, including 3 with stage IV-S, 2 with
stage II and 1 with stage I tumours, are all alive. All 4 dead
infants had a chromosome lp abnormality in the tumour
karyotype, and DMs/HSRs in 3. Of the 2 living infants,
however, with stage IV none was without structural tumour
chromosome aberrations. Patient Mo-K had a 6q-deletion
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Table I Major clinical, tumour-cytogenetic and tumour-DNA findings in 28 patients with neuroblastoma
Chromosome-
Age at Modal aberrations
diagnosis Survival number N-myc
Patient (mo) Sex (mo)a Outcome Stage Tissue (range) No. 1 dms hsr copiesb
JC-H 1 m 35 alive, NED I tu 58 (54-64) - - - nt
RZ-GI 73 f 44 alive, NED II tu (39-78) - - - nt
TT-DO 11 m 53 alive, NED II tu 70 (45-71) - - - nt
MJ-GI pp m 10 alive, NED II tu (82-84) - - - I
JS-DO 2 f 19 alive, NED IVs tu (55-60) - - - I
SB-S 1 f 33 alive, NED IVs tu (64-68) - - - nt
JK-NE 3 m 51 alive, NED IVs tu (56-58) - - - nt
MB-MR 54 m 75 alive III tu 60 (54-71) - - - I
MB-H 17 f 3 dead III tu 47 (46-47) + - + 30
FW-KS 43 m 29 alive, NED III tu (46-64) + - - nt
MO-K 9 f 25 alive IV bm (31-88) - - - 1
JF-GO 35 f 8 dead IV bm 46 (45-46)/ - - - 1
64 (63-66) - - - I
RB-GI 45 m 23 dead IV bm 46 (43-46) - - - 1
ME-HER 23 m 5 dead IV bm (30-83) + - -
MB-N 119 m 1 dead IV tu 57 (43-62) + - - nt
WW-BT 17 m 14 dead IV bm (80-108) + - - nt
SS-HD 11 m 6 dead IV bm 46 (26-46) + - - nt
SC-H 10 m 3 alive IV tu 73 (48-75) + + - nt
FO-ER 15 m 7 alive IV bm 46 (43-47) + + - 30
CR-GI 8 f 5 dead IV tu 46 (4447) + + - nt
bm 46 (45-46) + + - nt
VS-GI 15 f 7 dead IV bm 46 (44-48) + + - nt
SB-GI 26 m 16 dead IV tu 84 (82-90) + + - nt
bm 101 (99-103) + + - nt
AG-GI 30 f 17 dead IV bm (92-174) + + - nt
bm-rel (46-95) + + - nt
MG-N 9 f 16 dead IV bm 45 (38-48) + + - nt
bm-rel 46 (42-48)/ + + + 60
46 (43-47)/ + + + 60
46 (44 46) + - + 60
MH-NOH 43 f 32 dead III>IV ln 61 (44-73) + + + nt
SW-DO 35 f 13 dead III>IV bm 46 (42-47) + - + nt
MK-Wt 63 f 16 dead III>IV tu (34-88) + - + nt
SJ-B 9 m 4 dead III>IV bm (63-84) + - + nt
aSurvival, as of 1 July 1987; bSingle copy/haploid genome = 1. nt: not tested, pp: post partum, NED: no evidence of
disease, tu: tumour, bm: bone marrow, ln: lymphnode, rel: relapse.
but no Ip abnormality, but patient SC-H had a Ip trans-
location (Figure 1), and thus, prognosis in this case could be
bad in regard to the short observation time. All the other
infants are alive with no evidence of disease. None of them
had a lp abnormality (Figure 2) and/or DMs/HSRs in the
tumour karyotype, but all had hyperploid modal chromo-
some numbers of 58, 70, (82-84), (55-60), (64-68), (56-58),
(31-88), i.e. mainly in the triploid range.
In contrast, 13 of the 15 (87%), mainly older, patients
with stage IV neuroblastoma who already died, had an lp
aberrant karyotype, and 9 (60%) of them showed DMs
and/or HSRs. Modal chromosome numbers were in the
diploid range in about half of the patients. In the last 4
patients of the table, initially (probably falsely?) diagnosed as
stage III, tumour karyotyping was done later when
metastases were prominent.
As to morphology of the tumour chromosomes we
purposely selected for demonstration a complete and partial
karyotype from hyperploid primary tumours of infancy
(Figures 1 and 2) as these usually are more difficult to
prepare and analyze as compared to pseudodiploid tumour
cells from bone marrrow metastases.
In the 3 cases where 30-60 copies of the N-myc gene were
detected in the genome there were also DMs and/or HSRs in
the tumour karyotype. Lack of lp abnormality was also
associated with lack of N-myc amplification except for one
(already dead) patient (ME-HER) with stage IV and a
derivated chromosome 1. DMs and HSRs never occurred
simultaneously in the same metaphase cell but were
encountered in different metaphases of the same cell
population. HSRs were detected at different chromosomes
and on different arms, e.g. at 4p, 6q, 9q, 11q, 15p, 19q, 20q.
The only 2 non-surviving patients (JF-GO, RB-GI) with
stage IV and no lp abnormality nor DMs/HSRs or N-myc
amplification did show, however, other structural aberrations
and pseudodiploid tumour karyotype.
Overall, structural aberrations were found in the tumour
karyotypes of 23 patients (18 with stage IV, 3 with stage III,
2 with stage II) - whereas in 5 patients (3 with stage IV-S, 1
with stage II, 1 with stage I) only numerical aberrations were
present. As listed in Table II structural aberrations of the
tumour karyotype mainly affected the short arm of
chromosome 1. Other chromosomes not infrequently
involved were nos. 6, 11, 12, 17 (long arm).
As to localization of the breakpoint in the abnormal lp
tumour chromosome, 12 patients could be precisely
analyzed, and 1p32 was found to be the most frequently
involved (Figure 3). The correlation of karyotypic pattern -
taking the lp abnormality as the most characteristic
chromosome aberration - with survival could be demon-
strated in 26 patients by life table analysis (Kaplan-Meier
method, kindly carried out by Dr P. Kaatsch, Mainz)
(Figure 4). The two most recent patients SC-H, FO-ER with
stage IV were excluded because of insufficient observation
time. The clear-cut distinction between two groups of
patients with neuroblastoma is obvious: Patients (n = 11)TUMOUR KARYOTYPING IN NEUROBLASTOMA 123
Table II Tumour cell karyotypes in 28 patients with neuroblastoma
Modal Metaphases with additional structural aberrations
Number of Number of chromosome
metaphases metaphases number Ip aberrations:
Patient Tissue counted analyzed (range) Ip aberrations absol. perc.
1. JC-H tu 20 9 58 (54-64) - 0/9 (-) -
16
15
3
3
2
2
11
8
3
11
9
6
17
9
15
11
16
(39-78) -
70 (45-71) -
(82-84) -
(55-60) -
(64-68) -
(56-58) -
60 (54-71) -
47 (46-47) der(lp)
(46-64) t(l;?)(p36;?)
(31-88) -
46 (45-46)/ -
64 (63-66) -
46 (43-46) -
(30-83) der(lp)
57 (43-62) del(l)(p32)
(80-108) der(lp)
46 (26-46) t(l;?)(p22;?)
5 73 (48-75) t(l;?)(p22;?)
15 46 (43-47) del(l)(p22)
17 46 (44 47) t(l;1)(p32;pl5)
31 46 (45-46) t(l;l1)(p32;plS)
17 46 (44 48) t(l;1)(p32;q21)
31 84 (82-90) t(l;l3;?)(p32;q34;?)
18 101 (99-103) t(l;l3;?)(p32;q34;?)
32 (92-174) del(l)(p3?)
10 (46-95) del(l)(p3?)
11 45 (38-48) t(l;?)(p22;?)
13 46 (42-48)/ t(l;?)(p22;?)
34 46 (43-47)/ t(l;?)(p22;?)
16 46 (44-46) t(l;?)(p22;'?)
80 21 61 (44-73) dic(1)(p13)
26. SW-DO bm 43 17 46 (42-47) t(l;2)(p21;p36)
27. MK-WtY tu
28. SJ-B bm
12
11
(34-88) der(lp)
(63-84) t(l;?)(p32;?)
0/16 (-)
0/15 (-)
0/3 (-)
0/3 (-)
0/2 ()
0/2 (-)
0/11
2/8 (25%)
3/3 (100%)
0/11 (-)
0/9 (-)
0/6 (-)
0/17 (-)
9/9 (100%)
15/15 (100%)
7/11 (64%)
14/16 (88%)
5/5 (100%)
6/15 (40%)
17/17 (100%)
31/31 (100%)
15/17 (88%)
31/31 (100%)
18/18 (100%)
30/32 (94%)
10/10 (100%)
11/11 (100%)
13/13 (100%)
34/34 (100%)
16/16 (100%)
20/21 (95%)
17/17 (100%)
12/12 (100%)
11/11 (100%)
t (7;21)(p22;pl3), t(19;?)(pl3.1;?)
t(l9;?)(pl13;?)
der(lq), der(Sp), t(6;?)(q25;?), 2 mar
hsr(9)(q22), t(12;17)(ql4;q21), t(16;?)(pl3;?)
dup(12)(ql3q24), 2 mar
del(6)(q23)
del(l1)(ql3q21)
del(Il)(ql3q21), i(12q), t(13;?)(pll;?), I mar
del(3)(p21), del(ll)(pl1), 1 mar
6 mar
t(13;?)(q34;?), 4 mar
der(3q), der(9p), der( llq), der(l2p), der(l8q),
I mar
I mar, dms
dms
del(2)(p21), der(7p), dms
del(2)(p21), der(7p), dms
inv(2)(p3p23), t(8;?)(p;?), dms
inv(5)(plS;qll)del(q13.2), dms
inv(5)(p5;qll)del(q13.2), dms
der(lIp), 3 mar, dms
der(lIp), dms
t(2;?)(p24;?), dms
t(2;?)(p24;?), t(4;6)(q31;q25), hsr(lSp),
der(17q), dms
t(2;?)(p24;?), t(4;6)(q31;q25), hsr(15p),
der(17q), hsr(19q), dms
t(2;?)(p24;?), t(4;6)(q31;q25), hsr(15p),
der(17q), hsr(19q)
hsr(6)(q21), hsr(1l)(q25), t(6;X)(q21;ql3),
i(17q), 1 mar, dms
t(2;?)(p23;?), hsr(4)(p16), t(6;?)(ql5;?),
t(l0;?)(q24;?), hsr(I1)(q13), i(l7q), der(20p)
2 mar (hsr)
t(5;11)(qI3;q23)del(5)(qlIq13), del(l0)(pl1),
del(l2)(q13), hsr(20q)
tu: tumour, bm: bone marrow, In: lymph node, rel: relapse.
with a normal set of chromosome 1 in the tumour had a
probability of survival of 90% versus the patients (n=15)
with an aberrant chromosome 1 having less than 10%
survival probability. A comparison of lp-aberration versus
DMs/HSRs in the different stages of neuroblastomas shows
a more pronounced stage correlation of the chromosome lp
aberration (Figure 5).
Discussion
We succeeded in determining the tumour karyotype of 7
children with localized neuroblastoma stages I, II and stage
IV-S, the special congenital form of disseminated neuro-
blastoma. These patients are alive and have a good
prognosis. These cases were characterized oncocyto-
genetically by hyperploidy in the triploid range, lack of
chromosome lp abnormality and lack of cytogenetic
phenomena of gene amplification such as DMs and/or HSRs
(also confirmed by the absence of N-myc amplification). Our
observations are in accordance with recent data of Kaneko
et al. (1987) who found a near-triploid tumour lacking lp
abnormality and/or DMs, HSRs in 7 children with stage I or
II who were alive with no evidence of disease, and also with
data of 6 Japanese infants with stage I, II, III neuroblastoma
found by mass screening for vanillylmandelic acid in the
urine who only had hyperploid tumours with modal
chromosome numbers ranging from 67 to 71 as their sole
abnormality (Hayashi et al., 1986); By measuring the DNA
content of the tumour cells in 35 infants with neuroblastoma
(Look et al., 1984) it was also reported that hyperdiploidy
was associated with a better response to chemotherapy
compared to diploid tumours and that infants (n=4) with
IV-S stage had hyperdiploid tumour cells of clonal origin.
Another investigation by flow cytometric DNA analysis in
38 cases confirmed the favorable outcome in neuroblastoma
patients having an aneuploid tumour stem-line (Gansler et
al., 1986).
We would like to emphasize that karyotyping of the
tumour cell clone by analysis of individual chromosomes has
greater potential in discriminating two distinct prognostic
groups in children with neuroblastoma as compared to
cytophotometry on one hand, and N-myc determination on
the other. In particular, this can be shown in poor prognosis
patients, i.e. with stage IV disease: 83% (15 of 18) of our
patients with tumour dissemination, being either over or
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Figure 1 Complete karyotype of a hyperploid (mnn=73) cell from the primary tumour of a 10 month old infant with
neuroblastoma stage IV. Note the abnormal short arms of 2 chromosomes 1 with deletion and (unknown) translocation
(breakpoint at lp22), the presence of several DMs and one unidentified marker.
a b
p
q ... ....
MJ-GI, NB II, tu
(pp, m)
82, XXYY
Figure 2 Partial karyotype showing 4 normal chromosomes 1 (a) taken from a hyperploid (mn=82) cell; (b) of the primary
tumour of a newborn with neuroblastoma stage II.TUMOUR KARYOTYPING IN NEUROBLASTOMA 125
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Figure 3 Localization of breakpoints - where precise analysis
was possible - in the abnormal lp chromosome of the tumour
karyotype of 12 patients with neuroblastoma.
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Figure 4 Life table analysis (Kaplan-Meier method) of 26
patients with neuroblastoma of different stages with or without
chromosome lp abnormality in the tumour karyotype.
under one year, expressed a chromosome lp abnormality in
the tumour karyotype, with a diploid karyotype in only half
of the patients, 61% also had DMs and/or HSRs, but only
33% (2 of 6) of the few examined cases had N-myc
amplification. In the 13 patients with stage IV examined by
Kaneko et al. (1987) 9 (69%) had a lp abnormality, and 8
(62%) also had DMs/HSRs. Brodeur et al. (1984) found N-
myc amplification (more than 3 copies) in neuroblastoma
tissue from 13 of 25 (52%) untreated patients with stage IV,
and Seeger et al. (1985) in 19 of 40 (48%) patients with stage
IV. As one could expect a close correlation between N-myc
amplification and presence of DMs/HSRs in the karyotype,
as has also proven in one of our patients (MG-N) by in-situ
hybridization (Christiansen et al., 1987), multiple copies of
N-myc would be present in about 60% of patients with stage
IV. As a chromosome lp abnormality is encountered more
frequently in this stage of progressive tumour growth one
might speculate that the aberration of chromosome 1 distal
to band lp22 (Brodeur et al., 1981; Gilbert et al., 1984) or
lpl3 (our results) is the primary event, and gene amplifi-
cation is secondary, being rarely associated with morphologic
uniformity. As shown by our analysis, HSRs were
distributed among several chromosomes and different arms,
involving the short arm of chromosomes 4 and 15 and the
long arms of chromosomes 6, 9, 11, 19 and 20, and,
Figure 5 Distribution of the chromosome lp-aberration versus
DMs/HSRs in the tumour karyotype of 28 patients with neuro-
blastoma of different clinical stages.
interestingly, DMs were found in two different size groups in
a case of metastatic neuroblastoma (Franke, et al., 1985).
If one takes deletion of certain genes on the short arm of
one chromosome 1 as the crucial primary event for
aggressive growth in neuroblastomas, our life table analysis
can clearly distinguish two groups of patients - regardless of
stage and age - one with a less than 10% survival chance
versus the other with a 90% survival probability. This is
superior to N-myc oncogene determinations in that 55
patients with only a single copy of the gene in their tumour
DNA had an estimated survival rate of less than 60%
(Seeger et al., 1985).
Neuroblastoma cells with undisturbed homologues of
chromosome 1 - probably a completely different entity
-
might just be temporarily deregulated or because of
increased DNA content more vulnerable to chemotherapy.
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